Sign in
Taking people in United StatesPhase 1/2

Tests IDP-023 alone and with antibody drugs in advanced blood cancers

Tests IDP-023, alone or with other drugs, in adults with advanced lymphoma or myeloma.

Key facts

Who runs it
Indapta Therapeutics, INC.
Where
Atlanta, Cleveland, Fairfax, Houston, Lake Mary, Los Angeles, Minneapolis, Nashville, New York, Portland, Providence, and Winston-Salem, United StatesSee the 12 sites
Trial code
Registry title
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
Status
Recruiting
Phase
Phase 1/2
People taking part
128 people, planned
Started
25 Oct 2023
Expected to end
31 Dec 2029
Type of study
Interventional, 6 groups
Treatments tested
  • IDP-023
  • Rituximab
  • Daratumumab
  • Interleukin-2
  • Cyclophosphamide
  • Fludarabine
  • Mesna
  • Isatuximab
Record updated
3 June 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with advanced multiple myeloma or non-Hodgkin lymphoma that came back or did not respond to earlier treatment.

Age
18 years or older
Sex
All sexes can join
Disease stage
Multiple myeloma that needs systemic therapy and came back or did not respond. Or non-Hodgkin lymphoma that came back or did not respond.
Earlier treatment
Multiple myeloma: at least 3 earlier lines of therapy. Non-Hodgkin lymphoma: at least 2 earlier lines of systemic chemotherapy did not work.

Main reasons for not taking part

  • Impaired heart function or a history of serious heart disease
  • HIV infection, active hepatitis B infection, or hepatitis C infection
  • Active SARS-CoV-2 infection
  • Untreated cancer spread to the central nervous system, the epidural space or the brain

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • For MM patients: Documented diagnosis of MM requiring systemic therapy and relapsed and/or refractory (R/R) disease after ≥ 3 prior lines of therapy
  • For NHL patients: R/R disease and failed ≥ 2 lines of systemic chemotherapy
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • Life expectancy of greater than 12 weeks per the Investigator

Who cannot take part

  • Impaired cardiac function or history of clinical significant cardiac disease
  • Human immunodeficiency virus (HIV) infection, active hepatitis B infection, or hepatitis C infection
  • Active SARS-CoV-2 infection
  • Has untreated central nervous system, epidural tumor metastasis, or brain metastasis

Where in United States

  • Emory University HospitalAtlanta, United StatesContact: Indapta Therapeutics, Inc.Taking people
  • University Hospitals ClevelandCleveland, United StatesContact: Indapta Therapeutics, Inc.Taking people
  • NEXT Oncology- VirginiaFairfax, United StatesContact: Blake PattersonTaking people
  • University of Texas - MD Anderson Cancer CenterHouston, United StatesContact: Christy AllenTaking people
  • Florida Cancer Specialists and Research Institute - Lake Mary Cancer CenterLake Mary, United StatesContact: Indapta Therapeutics, Inc.No longer taking part
  • Valkyrie Clinical TrialsLos Angeles, United StatesContact: Myo ZawTaking people
  • University of MinnesotaMinneapolis, United StatesContact: Kayla Wagenmann, MN, RN, PHNTaking people
  • SCRI Oncology PartnersNashville, United StatesContact: Briana SmithTaking people
  • NYP/Weill Cornell Medical CenterNew York, United StatesContact: Indapta Therapeutics, Inc.No longer taking part
  • Providence Cancer Institute Franz ClinicPortland, United StatesContact: Indapta Therapeutics, Inc.No longer taking part
  • Rhode Island HospitalProvidence, United StatesContact: Stephen DonnellyTaking people
  • Atrium Health Wake Forest BaptistWinston-Salem, United StatesContact: Catalina Gonzalez-PinzonTaking people

About the trial

What the trial wants to find out

This is an open label, Phase 1/2, first-in-human, multiple ascending dose, and dose-expansion study of IDP-023 administered as a single agent and in combination with or without interleukin-2 (IL-2), and with or without isatuximab, daratumumab or rituximab to evaluate the safety, tolerability and preliminary antitumor activity in patients with advanced hematologic cancers.

The 6 groups in the trial

  • Phase 1: Single Agent IDP-023 - Single DoseTreatment being tested

    NHL or MM patient treated with a single dose of IDP-023 monotherapy

    Treatment: IDP-023, Cyclophosphamide, Fludarabine, and Mesna

  • Phase 1: Single Agent IDP-023 - Multiple DosesTreatment being tested

    NHL and MM patients treated with multiple doses of IDP-023 monotherapy

    Treatment: IDP-023, Cyclophosphamide, Fludarabine, and Mesna

  • Phase 1: Single Agent IDP-023 - Multiple Doses with IL-2Treatment being tested

    NHL and MM patients treated with multiple doses of IDP-023 monotherapy

    Treatment: IDP-023, Interleukin-2, Cyclophosphamide, Fludarabine, and Mesna

  • Phase 2: Combination IDP-023 plus rituximabTreatment being tested

    NHL patients treated with multiple doses of IDP-023 in combination with rituximab

    Treatment: IDP-023, Rituximab, Interleukin-2, Cyclophosphamide, Fludarabine, and Mesna

  • Phase 2: Combination IDP-023 plus daratumumabTreatment being tested

    MM patients treated with multiple doses of IDP-023 in combination with daratumumab

    Treatment: IDP-023, Daratumumab, Interleukin-2, Cyclophosphamide, Fludarabine, and Mesna

  • Phase 2: Combination IDP-023 plus isatuximabTreatment being tested

    MM patients treated with multiple doses of IDP-023 in combination with isatuximab

    Treatment: IDP-023, Interleukin-2, Cyclophosphamide, Fludarabine, Mesna, and Isatuximab

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Phase 1/2 Study of IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
Plain-language title
Tests IDP-023 alone and with antibody drugs in advanced blood cancersGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
3 June 2025